ClinicalTrials.gg
CompletedNCT02194985Updated Dec 21, 2020Results posted

Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease

A Phase 3 interventional study of migalastat HCl 150 mg in Fabry Disease, sponsored by Amicus Therapeutics. Completed at 28 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-21.

Sponsored by Amicus Therapeutics (part of BioMarin Pharmaceutical) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
84
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing migalastat in Fabry Disease — 2 open to participants now, 3 under way, 3 of them phase 3. migalastat · Fabry Disease.

Enrollment
4th of 20
84 · median 20
Started
2015
the only one that year
Phase 3
11 of 20
2 open now
Registered
13th of 20
by date
Lead sponsor
17 of 20
Amicus Therapeutics

Among the 20 studies testing migalastat in Fabry Disease, this one is the 4th largest by enrollment, is the only one that started in 2015, is one of 11 in phase 3, and was the 13th registered.

Fabry Disease

244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.

Browse Fabry Disease studies →

Open to participants now

2 of the 20 studies testing migalastat in Fabry Disease are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About migalastat

migalastat: first FDA approval 2018 (GALAFOLD), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing migalastat in Fabry Disease, or all of them as a file.
02

Study summary

This is an open-label extension study intended to provide continued treatment with migalastat hydrochloride (HCl) for participants with Fabry disease who completed treatment of a previous migalastat HCl study. The study assessed the long-term safety and effectiveness of migalastat HCl.

03

Conditions studied

  • Fabry Disease

Browse trials for

Keywords

  • Amicus Therapeutics
  • Galafold
  • Migalastat
  • AT1001
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant had completed treatment in a previous study of migalastat HCl given as a monotherapy
  • Male and female participant agreed to use protocol-identified acceptable
  • Participant was willing to provide written and authorization for use and disclosure of Personal Health Information (PHI)

Exclusion criteria

Exclusion Criteria:

  • Participant's last available estimated (eGFR) in the previous study was \<30 milliliter (mL)/minute (min)/1.73 meters squared (m\^2); unless there was measured GFR available within 3 months of Baseline Visit, which was >30 mL/min/1.73 m\^2
  • Participant had undergone, or was scheduled to undergo kidney transplantation or was currently on dialysis
  • Participant had a documented , stroke, unstable angina, or myocardial infarction within the 3 months before Baseline Visit
  • Participant had unstable cardiac disease in the opinion of the investigator (for example, cardiac disease requiring active management, such as symptomatic arrhythmia, unstable angina, or class III or IV congestive heart failure)
  • Participant had a history of allergy or sensitivity to AT1001 (including ) or other iminosugars (for example, miglustat, miglitol)
  • Participant required treatment with Glyset® (miglitol) or Zavesca® (miglustat)
  • Participants with severe or unsuitable concomitant medical condition
  • Participants with clinically significant abnormal laboratory value(s) and/or clinically significant (ECG) findings
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Migalastat HCl 150 mg

    Migalastat HCl 150 milligram (mg).

    Drug: migalastat HCl 150 mg

Interventions

  • Migalastat HCl 150 mg (equivalent to 123 mg migalastat) was provided as capsules in blister packs. One capsule was taken orally every other day.

    Also known as: AT1001, Galafold

06

What researchers measure

Primary outcomes

  1. Number Of Participants Experiencing Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence in a participant administered migalastat that did not necessarily have a causal relationship with the treatment. Each AE was recorded at time of reporting; visits typically occurred every 6 months. Serious AEs were life threatening or resulted in death, resulted in disability/incapacity, hospitalization or prolonged hospitalization, or a congenital anomaly. The criteria for AE severity were: Mild: awareness of sign or symptom, does not interfere with normal everyday activities; Moderate: discomforting, interferes with normal everyday activities, but able to function; Severe: incapacitating, prevents normal everyday activities or significantly affects clinical status and requires medical intervention. A summary of serious and all other non-serious AEs regardless of causality is located in the Reported Adverse Events module.

    Time frame: Day 1 after first dose to approximately 30 days after last treatment, median duration of 3.1 years

Secondary outcomes

  1. Annualized Rate Of Change In The Estimated Glomerular Filtration Rate (eGFR)

    The annualized rate of change in the eGFR was assessed per participant by the slope of the simple linear regression between the observed values and the assessment times. It was calculated by using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (eGFR \[CKD-EPI\]) and the Modification of Diet in Renal Disease (MDRD) equation (eGFR \[MDRD\]). The equations are as follows: eGFR \[MDRD\] = 175 × (1/Serum Creatinine in mg/deciliter\^1.154) × (1/Age in years\^0.203) × 0.742 \[if female\] × 1.212 \[if black\] × 0.808 \[if Japanese\]; eGFR \[CKD-EPI\] = 141 × min(Serum creatinine \[Scr\]/k, 1)α × max(Scr/k, 1) - 1.209 × 0.993Age × 1.018 \[if female\] × 1.159 \[if black\], where Scr is serum creatinine, k is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/k or 1, and max indicates the maximum of Scr/k or 1. Participants with at least a Baseline and a post-Baseline value are presented.

    Time frame: Baseline to approximately 30 days after last treatment, median duration of 3.1 years

  2. Change From Baseline In eGFR At End Of Study

    The change from baseline in eGFR was calculated using eGFR\[CKD-EPI\] and eGFR\[MDRD\] equations. Baseline was defined as the data collected at Month 0, if not available, it was the last visit of the previous (feeder) study if done within 6 months. End of Study was the last recorded observation for each participant (approximately 30 days after last treatment). Only participants with both a Baseline value and an End of Study value were included in the change from baseline analysis.

    Time frame: Baseline to approximately 30 days after last treatment, median duration of 3.1 years

  3. Change From Baseline In Plasma Globotriaosylsphingosine (Lyso-Gb3) To End Of Study

    Concentrations of lyso-Gb3 were measured in plasma using a qualified assay. Baseline was defined as the data collected at Month 0, if not available, it was the last visit of the previous (feeder) study if done within 6 months. End of study was the last recorded observation for each participant (approximately 30 days after last treatment). Only participants with both a Baseline value and an End of Study value were included in the change from baseline analysis.

    Time frame: Baseline to approximately 30 days after last treatment, median duration of 3.1 years

  4. Change From Baseline In White Blood Cell α-Gal A Activity To End Of Study

    The activity of the α-galactosidase A (α-Gal A) enzyme was measured in leukocyte lysate by a validated fluorometric assay method, using 4-methylumbelliferone as a reference. The activity values obtained were normalized to protein (measured using a colorimetric assay). Baseline was defined as the data collected at Month 0, if not available, it was the last visit of the previous (feeder) study if done within 6 months. End of Study was the last recorded observation for each participant (approximately 30 days after last treatment). Results for male participants are reported. Only participants with both a Baseline value and an End of Study value were included in the change from baseline analysis.

    Time frame: Baseline to approximately 30 days after last treatment, median duration of 3.1 years

  5. Change From Baseline In 24-hour Urine Protein To End Of Study

    A 24-hour urine sample was collected to measure 24-hour urine protein. Baseline was defined as the data collected at Month 0, if not available, it was the last visit of the previous (feeder) study if done within 6 months. End of Study was the last recorded observation for each participant (approximately 30 days after last treatment). Only participants with both a Baseline value and an End of Study value were included in the change from baseline analysis.

    Time frame: Baseline to approximately 30 days after last treatment, median duration of 3.1 years

  6. Change From Baseline In Left Ventricular Mass (LVM) To End Of Study

    LVM was measured by echocardiography. Baseline was defined as the data collected at Month 0, if not available, it was the last visit of the previous (feeder) study if done within 6 months. End of Study was the last recorded observation for each participant (approximately 30 days after last treatment). Only participants with both a Baseline value and an End of Study value were included in the change from baseline analysis.

    Time frame: Baseline to approximately 30 days after last treatment, median duration of 3.1 years

  7. Change From Baseline In Left Ventricular Mass Index (LVMi) To End Of Study

    LVMi was measured by echocardiography. Baseline was defined as the data collected at Month 0, if not available, it was the last visit of the previous (feeder) study if done within 6 months. End of Study was the last recorded observation for each participant (approximately 30 days after last treatment). Only participants with both a Baseline value and an End of Study value were included in the change from baseline analysis.

    Time frame: Baseline to approximately 30 days after last treatment, median duration of 3.1 years

  8. Change From Baseline In Patient Reported Quality Of Life To End Of Study, As Assessed By The Short Form-36 (SF-36) Questionnaire

    The SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile (Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, and Mental Health). Scores on each item are summed and averaged (range: 0=worst to 100=best). Scores were normed to the US population. Higher score indicates less disability. A positive change from baseline indicates improvement. Baseline was defined as the data collected in the last visit of the previous (feeder) study. Only participants with both a Baseline value and an End of Study value were included in the change from baseline analysis.

    Time frame: Baseline to approximately 30 days after last treatment, median duration of 3.1 years

07

Results

Posted Dec 21, 2020

Participant flow

Participant flow — Overall Study
MilestoneMigalastat HCl 150 mg
Started84
Received at least 1 dose of study drug84
Completed73
Not completed11
Withdrew: Adverse event1
Withdrew: Met protocol defined stopping criteria3
Withdrew: Physician decision4
Withdrew: Lost to follow-up1
Withdrew: Withdrawal by subject2

Outcome measures

PrimaryNumber Of Participants Experiencing Adverse Events (AEs)

An AE was defined as any untoward medical occurrence in a participant administered migalastat that did not necessarily have a causal relationship with the treatment. Each AE was recorded at time of reporting; visits typically occurred every 6 months. Serious AEs were life threatening or resulted in death, resulted in disability/incapacity, hospitalization or prolonged hospitalization, or a congenital anomaly. The criteria for AE severity were: Mild: awareness of sign or symptom, does not interfere with normal everyday activities; Moderate: discomforting, interferes with normal everyday activities, but able to function; Severe: incapacitating, prevents normal everyday activities or significantly affects clinical status and requires medical intervention. A summary of serious and all other non-serious AEs regardless of causality is located in the Reported Adverse Events module.

Time frame:
Day 1 after first dose to approximately 30 days after last treatment, median duration of 3.1 years
Reported as:
Count of participants · Participants
Number Of Participants Experiencing Adverse Events (AEs)
ParticipantsMigalastat HCl 150 mg
Participants with at least 1 AE80
Participants with at least 1 serious AE26
Participants discontinued due to AEs1
Participants with AEs leading to death0
Participants with AEs related to study drug24
Participants with AEs unrelated to study drug56
Participants with at least 1 mild AE19
Participants with at least 1 moderate AE46
Participants with at least 1 severe AE15
SecondaryAnnualized Rate Of Change In The Estimated Glomerular Filtration Rate (eGFR)

The annualized rate of change in the eGFR was assessed per participant by the slope of the simple linear regression between the observed values and the assessment times. It was calculated by using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (eGFR \[CKD-EPI\]) and the Modification of Diet in Renal Disease (MDRD) equation (eGFR \[MDRD\]). The equations are as follows: eGFR \[MDRD\] = 175 × (1/Serum Creatinine in mg/deciliter\^1.154) × (1/Age in years\^0.203) × 0.742 \[if female\] × 1.212 \[if black\] × 0.808 \[if Japanese\]; eGFR \[CKD-EPI\] = 141 × min(Serum creatinine \[Scr\]/k, 1)α × max(Scr/k, 1) - 1.209 × 0.993Age × 1.018 \[if female\] × 1.159 \[if black\], where Scr is serum creatinine, k is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/k or 1, and max indicates the maximum of Scr/k or 1. Participants with at least a Baseline and a post-Baseline value are presented.

Time frame:
Baseline to approximately 30 days after last treatment, median duration of 3.1 years
Reported as:
Mean · mL/min/1.73 m^2
Annualized Rate Of Change In The Estimated Glomerular Filtration Rate (eGFR)
mL/min/1.73 m^2Migalastat HCl 150 mg
eGFR[MDRD]-1.6107 ± 5.62761
eGFR[CKD-EPI]-1.3528 ± 4.84795
SecondaryChange From Baseline In eGFR At End Of Study

The change from baseline in eGFR was calculated using eGFR\[CKD-EPI\] and eGFR\[MDRD\] equations. Baseline was defined as the data collected at Month 0, if not available, it was the last visit of the previous (feeder) study if done within 6 months. End of Study was the last recorded observation for each participant (approximately 30 days after last treatment). Only participants with both a Baseline value and an End of Study value were included in the change from baseline analysis.

Time frame:
Baseline to approximately 30 days after last treatment, median duration of 3.1 years
Reported as:
Mean · mL/min/1.73 m^2
Change From Baseline In eGFR At End Of Study
mL/min/1.73 m^2Migalastat HCl 150 mg
Baseline eGFR[MDRD]79.0 ± 22.56
End of Study eGFR[MDRD]75.8 ± 22.90
Change from Baseline eGFR[MDRD]-1.4 ± 10.62
Baseline eGFR[CKD-EPI]84.70 ± 23.092
End of Study eGFR[CKD-EPI]82.02 ± 23.890
Change from Baseline eGFR[CKD-EPI]-0.93 ± 9.828
SecondaryChange From Baseline In Plasma Globotriaosylsphingosine (Lyso-Gb3) To End Of Study

Concentrations of lyso-Gb3 were measured in plasma using a qualified assay. Baseline was defined as the data collected at Month 0, if not available, it was the last visit of the previous (feeder) study if done within 6 months. End of study was the last recorded observation for each participant (approximately 30 days after last treatment). Only participants with both a Baseline value and an End of Study value were included in the change from baseline analysis.

Time frame:
Baseline to approximately 30 days after last treatment, median duration of 3.1 years
Reported as:
Mean · nmol/L
Change From Baseline In Plasma Globotriaosylsphingosine (Lyso-Gb3) To End Of Study
nmol/LMigalastat HCl 150 mg
Baseline13.317 ± 17.5428
End of Study11.758 ± 16.0662
Change from Baseline-1.054 ± 4.4885
SecondaryChange From Baseline In White Blood Cell α-Gal A Activity To End Of Study

The activity of the α-galactosidase A (α-Gal A) enzyme was measured in leukocyte lysate by a validated fluorometric assay method, using 4-methylumbelliferone as a reference. The activity values obtained were normalized to protein (measured using a colorimetric assay). Baseline was defined as the data collected at Month 0, if not available, it was the last visit of the previous (feeder) study if done within 6 months. End of Study was the last recorded observation for each participant (approximately 30 days after last treatment). Results for male participants are reported. Only participants with both a Baseline value and an End of Study value were included in the change from baseline analysis.

Time frame:
Baseline to approximately 30 days after last treatment, median duration of 3.1 years
Reported as:
Mean · nmol/hr/mg
Change From Baseline In White Blood Cell α-Gal A Activity To End Of Study
nmol/hr/mgMigalastat HCl 150 mg
Baseline6.882 ± 6.6857
End of Study5.290 ± 5.4054
Change from Baseline-1.375 ± 3.3432
SecondaryChange From Baseline In 24-hour Urine Protein To End Of Study

A 24-hour urine sample was collected to measure 24-hour urine protein. Baseline was defined as the data collected at Month 0, if not available, it was the last visit of the previous (feeder) study if done within 6 months. End of Study was the last recorded observation for each participant (approximately 30 days after last treatment). Only participants with both a Baseline value and an End of Study value were included in the change from baseline analysis.

Time frame:
Baseline to approximately 30 days after last treatment, median duration of 3.1 years
Reported as:
Mean · mg/day
Change From Baseline In 24-hour Urine Protein To End Of Study
mg/dayMigalastat HCl 150 mg
Baseline478.9 ± 948.59
End of Study394.0 ± 547.77
Change from Baseline5.4 ± 233.49
SecondaryChange From Baseline In Left Ventricular Mass (LVM) To End Of Study

LVM was measured by echocardiography. Baseline was defined as the data collected at Month 0, if not available, it was the last visit of the previous (feeder) study if done within 6 months. End of Study was the last recorded observation for each participant (approximately 30 days after last treatment). Only participants with both a Baseline value and an End of Study value were included in the change from baseline analysis.

Time frame:
Baseline to approximately 30 days after last treatment, median duration of 3.1 years
Reported as:
Mean · gram
Change From Baseline In Left Ventricular Mass (LVM) To End Of Study
gramMigalastat HCl 150 mg
Baseline178.879 ± 78.6761
End of Study157.896 ± 47.9947
Change from Baseline-0.803 ± 18.8522
SecondaryChange From Baseline In Left Ventricular Mass Index (LVMi) To End Of Study

LVMi was measured by echocardiography. Baseline was defined as the data collected at Month 0, if not available, it was the last visit of the previous (feeder) study if done within 6 months. End of Study was the last recorded observation for each participant (approximately 30 days after last treatment). Only participants with both a Baseline value and an End of Study value were included in the change from baseline analysis.

Time frame:
Baseline to approximately 30 days after last treatment, median duration of 3.1 years
Reported as:
Mean · g/m^2
Change From Baseline In Left Ventricular Mass Index (LVMi) To End Of Study
g/m^2Migalastat HCl 150 mg
Baseline96.513 ± 36.5691
End of Study83.912 ± 22.7633
Change from Baseline-0.809 ± 11.8056
SecondaryChange From Baseline In Patient Reported Quality Of Life To End Of Study, As Assessed By The Short Form-36 (SF-36) Questionnaire

The SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile (Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, and Mental Health). Scores on each item are summed and averaged (range: 0=worst to 100=best). Scores were normed to the US population. Higher score indicates less disability. A positive change from baseline indicates improvement. Baseline was defined as the data collected in the last visit of the previous (feeder) study. Only participants with both a Baseline value and an End of Study value were included in the change from baseline analysis.

Time frame:
Baseline to approximately 30 days after last treatment, median duration of 3.1 years
Reported as:
Mean · units on a scale
Change From Baseline In Patient Reported Quality Of Life To End Of Study, As Assessed By The Short Form-36 (SF-36) Questionnaire
units on a scaleMigalastat HCl 150 mg
Baseline Physical Functioning48.313 ± 9.2345
End of Study Physical Functioning46.415 ± 10.2466
Change from Baseline Physical Functioning-1.276 ± 7.1627
Baseline Role Physical46.197 ± 10.0761
End of Study Role Physical45.929 ± 10.5723
Change from Baseline Role Physical0.390 ± 7.3500
Baseline Bodily Pain46.889 ± 10.5983
End of Study Bodily Pain46.737 ± 10.3368
Change from Baseline Bodily Pain0.425 ± 8.1342
Baseline General Health44.016 ± 10.2497
End of Study General Health42.352 ± 10.1185
Change from Baseline General Health-0.811 ± 5.8672
Baseline Vitality46.375 ± 11.8451
End of Study Vitality45.429 ± 12.4340
Change from Baseline Vitality-0.674 ± 8.5076
Baseline Social Functioning47.433 ± 10.4985
End of Study Social Functioning47.648 ± 9.5165
Change from Baseline Social Functioning0.401 ± 8.4356
Baseline Role Emotional47.547 ± 10.3897
End of Study Role Emotional46.141 ± 10.9054
Change from Baseline Role Emotional-0.929 ± 10.6679
Baseline Mental Health48.501 ± 10.6878
End of Study Mental Health49.578 ± 10.5732
Change from Baseline Mental Health0.872 ± 6.2528
Baseline Physical Component46.184 ± 10.2268
End of Study Physical Component44.825 ± 10.4292
Change from Baseline Physical Component-0.508 ± 6.2494
Baseline Mental Component47.917 ± 11.5480
End of Study Mental Component48.175 ± 10.9497
Change from Baseline Mental Component0.187 ± 8.2714

Adverse events

Collected over Baseline to up to 4.4 years (includes safety follow-up). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Migalastat HCl 150 mg0/84 (0%)26/84 (31%)74/84 (88.1%)
Most frequent serious events
Showing 10 of 45
Most frequent serious events
EventMigalastat HCl 150 mg
Atrial fibrillationCardiac disorders2/84
DehydrationMetabolism and nutrition disorders2/84
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/84
DyspnoeaRespiratory, thoracic and mediastinal disorders2/84
Atrioventricular block completeCardiac disorders1/84
Left ventricular hypertrophyCardiac disorders1/84
Ventricular tachycardiaCardiac disorders1/84
Visual impairmentEye disorders1/84
Abdominal painGastrointestinal disorders1/84
Abdominal pain upperGastrointestinal disorders1/84
Most frequent other events
Showing 10 of 51
Most frequent other events
EventMigalastat HCl 150 mg
NasopharyngitisInfections and infestations17/84
FatigueGeneral disorders16/84
ArthralgiaMusculoskeletal and connective tissue disorders16/84
Pain in extremityMusculoskeletal and connective tissue disorders14/84
ParaesthesiaNervous system disorders13/84
Oedema peripheralGeneral disorders12/84
Upper respiratory tract infectionInfections and infestations12/84
Urinary tract infectionInfections and infestations12/84
OverdoseInjury, poisoning and procedural complications12/84
HeadacheNervous system disorders12/84

Baseline characteristics

All participants who took at least 1 dose of the study drug after they had enrolled into this study.

Age, Continuous
Age, Continuous(years)Migalastat HCl 150 mg
Mean51.9 ± 12.27
Sex: Female, Male
Sex: Female, Male(Participants)Migalastat HCl 150 mg
Female50
Male34
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Migalastat HCl 150 mg
Hispanic or Latino5
Not Hispanic or Latino41
Unknown or Not Reported38
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Migalastat HCl 150 mg
American Indian or Alaska Native0
Asian6
Native Hawaiian or Other Pacific Islander0
Black or African American0
White78
More than one race0
Unknown or Not Reported0
08

Study locations

28 sites
  • Clinical Study Site
    Atlanta, Georgia 30322, United States
  • Clinical Study Site
    Kansas City, Kansas 66160, United States
  • Clinical Study Site
    Grand Rapids, Michigan 49525, United States
  • Clinical Study Site
    New York, New York 10016, United States
  • Clinical Study Site
    Portland, Oregon 97239, United States
  • Clinical Study Site
    Dallas, Texas 75226, United States
  • Clinical Study Site
    Fairfax, Virginia 22030, United States
  • Clinical Study Site
    Pilar, B1629ODT, Argentina
  • Clinical Study Site
    Adelaide, 5000, Australia
  • Clinical Study Site
    Parkville, 3050, Australia
  • Clinical Study Site
    Wien, 1090, Austria
  • Clinical Study Site
    Edegem, 2650, Belgium
  • Clinical Study Site
    Porto Alegre, 90035-903, Brazil
  • Clinical Study Site
    Montreal, Quebec H4J 1C5, Canada
  • Clinical Study Site
    Copenhagen, 2100, Denmark
  • Clinical Study Site
    Cairo, 11451, Egypt
  • Clinical Study Site
    Garches, 92380, France
  • Clinical Study Site
    Lille, 59037, France
  • Clinical Study Site
    Firenze, 50134, Italy
  • Clinical Study Site
    Roma, 00168, Italy
  • Clinical Study Site
    Suita, Osaka 565-0871, Japan
  • Clinical Study Site
    Niigata, 951-8520, Japan
  • Clinical Study Site
    Osaka-shi, 545-8586, Japan
  • Clinical Study Site
    Tokyo, 105-8471, Japan
  • Clinical Study Site
    Barcelona, 08025, Spain
  • Clinical Study Site
    Ankara, 06500, Turkey
  • Clinical Study Site
    London, NW3 2QG, United Kingdom
  • Clinical Study Site
    London, WC1N3BG, United Kingdom
09

References and documents

Publications

  • Narita I, Ohashi T, Sakai N, Hamazaki T, Skuban N, Castelli JP, Lagast H, Barth JA. Efficacy and safety of migalastat in a Japanese population: a subgroup analysis of the ATTRACT study. Clin Exp Nephrol. 2020 Feb;24(2):157-166. doi: 10.1007/s10157-019-01810-w. Epub 2019 Dec 30. PubMed 31889231 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2015 to primary completion in Oct 2019, 55 months.

Results were first posted in Dec 2020, 1 year 1 month after primary completion.

Of 22 phase 3 interventional studies under Fabry Disease, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 64. This study's 55 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2014
First posted
Jul 21, 2014
StartActual
Mar 14, 2015
Primary completionActual
Oct 23, 2019
CompletionActual
Oct 23, 2019
Results first posted
Dec 21, 2020
Last update
Dec 21, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 21, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02194985
Responsible party
Sponsor
First posted
Jul 21, 2014
Start date
Mar 14, 2015
Primary completion
Oct 23, 2019
Completion
Oct 23, 2019
Results posted
Dec 21, 2020
Last update
Dec 21, 2020

Study contacts

Medical Monitor Clinical Research
study director · Amicus Therapeutics

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Migalastat

Start the discussion